You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Ibrexafungerp (formerly SCY-078 or MK-3118): Comparison
View Latest Version
Please note this is a comparison between Version 2 by Rita Xu and Version 1 by SABELLE JALLOW.

Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or “fungerp” that inhibits biosynthesis of β-(1,3)-D-glucan in the fungal cell wall, a mechanism of action similar to that of echinocandins. Distinguishing characteristics of ibrexafungerp include oral bioavailability, a favourable safety profile, few drug-drug interactions, good tissue penetration, increased activity at low pH and activity against multi-drug resistant isolates including

C. auris

and

C. glabrata

. In vitro data has demonstrated broad and potent activity against Candida and

Aspergillus

species. Importantly, ibrexafungerp also has potent activity against azole-resistant isolates, including biofilm-forming

Candida

spp., and echinocandin-resistant isolates. It also has activity against the asci form of

Pneumocystis

spp., and other pathogenic fungi including some non-Candida yeasts and non-

Aspergillus

moulds. In vivo data have shown IBX to be effective for treatment of candidiasis and aspergillosis. Ibrexafungerp is effective for the treatment of acute vulvovaginal candidiasis in completed phase 3 clinical trials.

  • ibrexafungerp (IBX)
  • SCY-078
  • MK-3118
  • fungal cell wall
  • glucan synthase inhibitor
  • triterpenoid antifungal
  • fungerp
Please wait, diff process is still running!

References

  1. Douglas, C.M. Fungal beta(1,3)-D-glucan synthesis. Med. Mycol. 2001, 39 (Suppl. S1), 55–66.
  2. Mikamo, H.; Sato, Y.; Tamaya, T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother. 2000, 46, 485–487.
  3. Denning, D.W. Echinocandin antifungal drugs. Lancet 2003, 362, 1142–1151.
  4. Merck Research Laboratories. Cancidas (Caspofungin Acetate) Injection. Application No.: 21-227. Approval Date: 26 January 2001. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Special Pathogen and Immunologic Drug Products. Available online: (accessed on 29 December 2020).
  5. Feldmesser, M.; Kress, Y.; Mednick, A.; Casadevall, A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. 2000, 182, 1791–1795.
  6. Kurtz, M.B.; Rex, J.H. Glucan synthase inhibitors as antifungal agents. Adv. Protein Chem. 2001, 56, 423–475.
  7. Chandrasekar, P.H.; Sobel, J.D. Micafungin: A new echinocandin. Clin. Infect. Dis. 2006, 42, 1171–1178.
  8. Vazquez, J.A.; Sobel, J.D. Anidulafungin: A novel echinocandin. Clin. Infect. Dis. 2006, 43, 215–222.
  9. Pelaez, F.; Cabello, A.; Platas, G.; Diez, M.T.; Gonzalez del Val, A.; Basilio, A.; Martan, I.; Vicente, F.; Bills, G.E.; Giacobbe, R.A.; et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst. Appl. Microbiol. 2000, 23, 333–343.
  10. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-.PubChem Compound Summary. Available online: (accessed on 30 December 2020).
  11. Coad, B.R.; Lamont-Friedrich, S.J.; Gwynne, L.; Jasieniak, M.; Griesser, S.S.; Traven, A.; Peleg, A.Y.; Griesser, H.J. Surface coatings with covalently attached caspofungin are effective in eliminating fungal pathogens. J. Mater. Chem. B 2015, 3, 8469–8476.
  12. Onishi, J.; Meinz, M.; Thompson, J.; Curotto, J.; Dreikorn, S.; Rosenbach, M.; Douglas, C.; Abruzzo, G.; Flattery, A.; Kong, L.; et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 2000, 44, 368–377.
  13. Davis, M.R.; Donnelley, M.A.; Thompson, G.R. Ibrexafungerp: A novel oral glucan synthase inhibitor. Med. Mycol. 2020, 58, 579–592.
  14. Azie, N. A Phase 2b, Dose Finding Study Evaluating Oral Ibrexafungerp in Moderate to Severe Acute Vulvovaginal Candidiasis (DOVE). In Proceedings of the 3rd ISIDOG Congress, Porto, Portugal, 31 Octorber–3 November 2019; Available online: (accessed on 29 December 2020).
  15. Apgar, J.M.; Wilkening, R.R.; Parker, D.L., Jr.; Meng, D.; Wildonger, K.J.; Sperbeck, D.; Greenlee, M.L.; Balkovec, J.M.; Flattery, A.M.; Abruzzo, G.K.; et al. Ibrexafungerp: An orally active beta-1,3-glucan synthesis inhibitor. Bioorg. Med. Chem. Lett. 2020.
  16. Scynexis. The World Health Organization Recognizes New Antifungal Class by Granting “ibrexafungerp” to SCYNEXIS as the International Non-Proprietary Name for SCY-078. SCYNEXIS, Inc. Press Release Online. 2018. Available online: (accessed on 29 December 2020).
  17. Garcia-Rubio, R.; de Oliveira, H.C.; Rivera, J.; Trevijano-Contador, N. The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species. Front. Microbiol. 2019, 10, 2993.
  18. Ruiz-Herrera, J.; Ortiz-Castellanos, L. Cell wall glucans of fungi. A review. Cell Surf. 2019, 5, 100022.
  19. Fleet, G.H. Composition and structure of yeast cell walls. Curr. Top Med. Mycol. 1985, 1, 24–56.
  20. Deresinski, S.C.; Stevens, D.A. Caspofungin. Clin. Infect. Dis. 2003, 36, 1445–1457.
  21. Latge, J.P. The cell wall: A carbohydrate armour for the fungal cell. Mol. Microbiol. 2007, 66, 279–290.
  22. Mazur, P.; Morin, N.; Baginsky, W.; el-Sherbeini, M.; Clemas, J.A.; Nielsen, J.B.; Foor, F. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol. Cell Biol. 1995, 15, 5671–5681.
  23. Dijkgraaf, G.J.; Abe, M.; Ohya, Y.; Bussey, H. Mutations in Fks1p affect the cell wall content of beta-1,3- and beta-1,6-glucan in Saccharomyces cerevisiae. Yeast 2002, 19, 671–690.
  24. Kondoh, O.; Tachibana, Y.; Ohya, Y.; Arisawa, M.; Watanabe, T. Cloning of the RHO1 gene from Candida albicans and its regulation of beta-1,3-glucan synthesis. J. Bacteriol. 1997, 179, 7734–7741.
  25. Shematek, E.M.; Braatz, J.A.; Cabib, E. Biosynthesis of the yeast cell wall. I. Preparation and properties of beta-(1 leads to 3) glucan synthetase. J. Biol. Chem. 1980, 255, 888–894.
  26. Pfaller, M.A.; Messer, S.A.; Motyl, M.R.; Jones, R.N.; Castanheira, M. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob. Agents Chemother. 2013, 57, 1065–1068.
  27. Walker, S.S.; Xu, Y.; Triantafyllou, I.; Waldman, M.F.; Mendrick, C.; Brown, N.; Mann, P.; Chau, A.; Patel, R.; Bauman, N.; et al. Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 2011, 55, 5099–5106.
  28. Scorneaux, B.; Angulo, D.; Borroto-Esoda, K.; Ghannoum, M.; Peel, M.; Wring, S. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. Antimicrob. Agents Chemother. 2017, 61.
  29. Bowman, J.C.; Hicks, P.S.; Kurtz, M.B.; Rosen, H.; Schmatz, D.M.; Liberator, P.A.; Douglas, C.M. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 2002, 46, 3001–3012.
  30. Ghannoum, M.; Long, L.; Larkin, E.L.; Isham, N.; Sherif, R.; Borroto-Esoda, K.; Barat, S.; Angulo, D. Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis. Antimicrob. Agents Chemother. 2018, 62.
  31. Jimenez-Ortigosa, C.; Perez, W.B.; Angulo, D.; Borroto-Esoda, K.; Perlin, D.S. De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance. Antimicrob. Agents Chemother. 2017, 61.
  32. Perlin, D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 2007, 10, 121–130.
  33. Garcia-Effron, G.; Lee, S.; Park, S.; Cleary, J.D.; Perlin, D.S. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: Implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 2009, 53, 3690–3699.
  34. Park, S.; Kelly, R.; Kahn, J.N.; Robles, J.; Hsu, M.J.; Register, E.; Li, W.; Vyas, V.; Fan, H.; Abruzzo, G.; et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 2005, 49, 3264–3273.
  35. Ben-Ami, R.; Garcia-Effron, G.; Lewis, R.E.; Gamarra, S.; Leventakos, K.; Perlin, D.S.; Kontoyiannis, D.P. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J. Infect. Dis. 2011, 204, 626–635.
  36. Alexander, B.D.; Johnson, M.D.; Pfeiffer, C.D.; Jimenez-Ortigosa, C.; Catania, J.; Booker, R.; Castanheira, M.; Messer, S.A.; Perlin, D.S.; Pfaller, M.A. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 2013, 56, 1724–1732.
  37. Pham, C.D.; Iqbal, N.; Bolden, C.B.; Kuykendall, R.J.; Harrison, L.H.; Farley, M.M.; Schaffner, W.; Beldavs, Z.G.; Chiller, T.M.; Park, B.J.; et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob. Agents Chemother. 2014, 58, 4690–4696.
  38. Chowdhary, A.; Prakash, A.; Sharma, C.; Kordalewska, M.; Kumar, A.; Sarma, S.; Tarai, B.; Singh, A.; Upadhyaya, G.; Upadhyay, S.; et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J. Antimicrob. Chemother. 2018, 73, 891–899.
  39. Kordalewska, M.; Lee, A.; Park, S.; Berrio, I.; Chowdhary, A.; Zhao, Y.; Perlin, D.S. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris. Antimicrob. Agents Chemother. 2018, 62.
  40. Naicker, S.D.; Magobo, R.E.; Zulu, T.G.; Maphanga, T.G.; Luthuli, N.; Lowman, W.; Govender, N.P. Two echinocandin-resistant Candida glabrata FKS mutants from South Africa. Med. Mycol. Case Rep. 2016, 11, 24–26.
  41. Nunnally, N.S.; Etienne, K.A.; Angulo, D.; Lockhart, S.R.; Berkow, E.L. In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations. Antimicrob. Agents Chemother. 2019, 63.
  42. Perfect, J.R. The antifungal pipeline: A reality check. Nat. Rev. Drug Discov. 2017, 16, 603–616.
  43. Pfaller, M.A.; Pappas, P.G.; Wingard, J.R. Invasive Fungal Pathogens: Current Epidemiological Trends. Clin. Infect. Dis. 2006, 43, S3–S14.
  44. Brown, G.D.; Denning, D.W.; Gow, N.A.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012, 4, 165rv113.
  45. WHO. Antimicrobial Resistance: Global Report on Surveillance; WHO (World Health Organization): Geneva, Switzerland, 2014; Available online: (accessed on 5 January 2021).
  46. Arendrup, M.C. Update on antifungal resistance in Aspergillus and Candida. Clin. Microbiol. Infect. 2014, 20 (Suppl. S6), 42–48.
  47. Pfaller, M.A.; Diekema, D.J. Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 2004, 42, 4419–4431.
  48. Wickes, B.L. Analysis of a Candida auris Outbreak Provides New Insights into an Emerging Pathogen. J. Clin. Microbiol. 2020, 58.
  49. Van Schalkwyk, E.; Mpembe, R.S.; Thomas, J.; Shuping, L.; Ismail, H.; Lowman, W.; Karstaedt, A.S.; Chibabhai, V.; Wadula, J.; Avenant, T.; et al. Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016–2017(1). Emerg. Infect. Dis. 2019, 25, 1698–1707.
  50. Govender, N.P.; Patel, J.; Magobo, R.E.; Naicker, S.; Wadula, J.; Whitelaw, A.; Coovadia, Y.; Kularatne, R.; Govind, C.; Lockhart, S.R.; et al. Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: Results from laboratory-based sentinel surveillance in South Africa. J. Antimicrob. Chemother. 2016, 71, 1994–2004.
  51. Fridkin, S.K.; Jarvis, W.R. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 1996, 9, 499–511.
  52. Pfaller, M.A.; Messer, S.A.; Moet, G.J.; Jones, R.N.; Castanheira, M. Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int. J. Antimicrob. Agents 2011, 38, 65–69.
  53. Chowdhary, A.; Sharma, C.; Duggal, S.; Agarwal, K.; Prakash, A.; Singh, P.K.; Jain, S.; Kathuria, S.; Randhawa, H.S.; Hagen, F.; et al. New clonal strain of Candida auris, Delhi, India. Emerg. Infect. Dis. 2013, 19, 1670–1673.
  54. Chowdhary, A.; Kumar, V.A.; Sharma, C.; Prakash, A.; Agarwal, K.; Babu, R.; Dinesh, K.R.; Karim, S.; Singh, S.K.; Hagen, F.; et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33, 919–926.
  55. Lockhart, S.R.; Etienne, K.A.; Vallabhaneni, S.; Farooqi, J.; Chowdhary, A.; Govender, N.P.; Colombo, A.L.; Calvo, B.; Cuomo, C.A.; Desjardins, C.A.; et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin. Infect. Dis. 2017, 64, 134–140.
  56. Lockhart, S.R.; Jackson, B.R.; Vallabhaneni, S.; Ostrosky-Zeichner, L.; Pappas, P.G.; Chiller, T. Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris. J. Clin. Microbiol. 2017, 55, 3324–3327.
  57. Zhu, Y.C.; Barat, S.A.; Borroto-Esoda, K.; Angulo, D.; Chaturvedi, S.; Chaturvedi, V. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int. J. Antimicrob. Agents 2020, 55, 105922.
  58. Ostrowsky, B.; Greenko, J.; Adams, E.; Quinn, M.; O’Brien, B.; Chaturvedi, V.; Berkow, E.; Vallabhaneni, S.; Forsberg, K.; Chaturvedi, S.; et al. Candida auris Isolates Resistant to Three Classes of Antifungal Medications-New York, 2019. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 6–9.
  59. Osei Sekyere, J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen 2018, 7, e00578.
  60. Sabino, R.; Verissimo, C.; Pereira, A.A.; Antunes, F. Candida auris, an Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind? Microorganisms 2020, 8, 181.
  61. Chaabane, F.; Graf, A.; Jequier, L.; Coste, A.T. Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris. Front Microbiol. 2019, 10, 2788.
  62. Forsberg, K.; Woodworth, K.; Walters, M.; Berkow, E.L.; Jackson, B.; Chiller, T.; Vallabhaneni, S. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen. Med. Mycol. 2019, 57, 1–12.
  63. Govender, N.P.; Magobo, R.E.; Mpembe, R.; Mhlanga, M.; Matlapeng, P.; Corcoran, C.; Govind, C.; Lowman, W.; Senekal, M.; Thomas, J. Candida auris in South Africa, 2012–2016. Emerg. Infect. Dis. 2018, 24, 2036–2040.
  64. Magobo, R.E.; Corcoran, C.; Seetharam, S.; Govender, N.P. Candida auris-associated candidemia, South Africa. Emerg. Infect. Dis. 2014, 20, 1250–1251.
  65. Patterson, T.F.; Kirkpatrick, W.R.; White, M.; Hiemenz, J.W.; Wingard, J.R.; Dupont, B.; Rinaldi, M.G.; Stevens, D.A.; Graybill, J.R. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine 2000, 79, 250–260.
  66. Lin, S.J.; Schranz, J.; Teutsch, S.M. Aspergillosis case-fatality rate: Systematic review of the literature. Clin. Infect. Dis. 2001, 32, 358–366.
  67. Vermeulen, E.; Maertens, J.; de Bel, A.; Nulens, E.; Boelens, J.; Surmont, I.; Mertens, A.; Boel, A.; Lagrou, K. Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. Antimicrob. Agents Chemother. 2015, 59, 4569–4576.
  68. Snelders, E.; van der Lee, H.A.; Kuijpers, J.; Rijs, A.J.; Varga, J.; Samson, R.A.; Mellado, E.; Donders, A.R.; Melchers, W.J.; Verweij, P.E. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008, 5, e219.
  69. Snelders, E.; Huis In ‘t Veld, R.A.; Rijs, A.J.; Kema, G.H.; Melchers, W.J.; Verweij, P.E. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 2009, 75, 4053–4057.
  70. Mitchell, T.G.; Perfect, J.R. Cryptococcosis in the era of AIDS–100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 1995, 8, 515–548.
  71. Walzer, P.D.; Evans, H.E.; Copas, A.J.; Edwards, S.G.; Grant, A.D.; Miller, R.F. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin. Infect. Dis. 2008, 46, 625–633.
  72. Duncan, R.A.; von Reyn, C.F.; Alliegro, G.M.; Toossi, Z.; Sugar, A.M.; Levitz, S.M. Idiopathic CD4+ T-lymphocytopenia--four patients with opportunistic infections and no evidence of HIV infection. N. Engl. J. Med. 1993, 328, 393–398.
  73. Reid, A.B.; Chen, S.C.; Worth, L.J. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: New risks and diagnostic tools. Curr. Opin. Infect. Dis. 2011, 24, 534–544.
  74. Porollo, A.; Meller, J.; Joshi, Y.; Jaiswal, V.; Smulian, A.G.; Cushion, M.T. Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome. Curr. Drug Targets 2012, 13, 1575–1585.
  75. Kaneshiro, E.S.; Ellis, J.E.; Jayasimhulu, K.; Beach, D.H. Evidence for the presence of “metabolic sterols” in Pneumocystis: Identification and initial characterization of Pneumocystis carinii sterols. J. Eukaryot Microbiol. 1994, 41, 78–85.
  76. Malamba, S.; Sandison, T.; Lule, J.; Reingold, A.; Walker, J.; Dorsey, G.; Mermin, J. Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am. J. Trop. Med. Hyg. 2010, 82, 766–771.
  77. Chen, S.C.; Slavin, M.A.; Sorrell, T.C. Echinocandin antifungal drugs in fungal infections: A comparison. Drugs 2011, 71, 11–41.
  78. Eschenauer, G.; Depestel, D.D.; Carver, P.L. Comparison of echinocandin antifungals. Ther. Clin. Risk Manag. 2007, 3, 71–97.
  79. De la Torre, P.; Meyer, D.K.; Reboli, A.C. Anidulafungin: A novel echinocandin for candida infections. Future Microbiol. 2008, 3, 593–601.
  80. Jimenez-Ortigosa, C.; Paderu, P.; Motyl, M.R.; Perlin, D.S. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. Antimicrob. Agents Chemother. 2014, 58, 1248–1251.
  81. Cushion, M.; Ashbaugh, A.; Borroto-Esoda, K.; Barat, S.A.; Angulo, D. SCY-078 demonstrates antifungal activity against pneumocystis in a prophylactic murine model of pneumocystis pneumonia. ASM Microbe Online 2018.
  82. Espinel-Ingroff, A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 1998, 36, 2950–2956.
  83. Maligie, M.A.; Selitrennikoff, C.P. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob. Agents Chemother. 2005, 49, 2851–2856.
  84. Marcos-Zambrano, L.J.; Gomez-Perosanz, M.; Escribano, P.; Bouza, E.; Guinea, J. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. J. Antimicrob. Chemother. 2017, 72, 1969–1976.
  85. Larkin, E.; Hager, C.; Chandra, J.; Mukherjee, P.K.; Retuerto, M.; Salem, I.; Long, L.; Isham, N.; Kovanda, L.; Borroto-Esoda, K.; et al. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob. Agents Chemother. 2017, 61.
  86. Pfaller, M.A.; Messer, S.A.; Rhomberg, P.R.; Borroto-Esoda, K.; Castanheira, M. Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species. Antimicrob. Agents Chemother. 2017, 61.
  87. Schell, W.A.; Jones, A.M.; Borroto-Esoda, K.; Alexander, B.D. Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species. Antimicrob. Agents Chemother. 2017, 61.
  88. Berkow, E.L.; Angulo, D.; Lockhart, S.R. In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. Antimicrob. Agents Chemother. 2017, 61.
  89. Ghannoum, M.; Long, L.; Isham, N.; Hager, C.; Wilson, R.; Borroto-Esoda, K.; Barat, S.; Angulo, D. Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against Candida glabrata. Antimicrob. Agents Chemother. 2019.
  90. Arendrup, M.C.; Jorgensen, K.M.; Hare, R.K.; Chowdhary, A. In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents. Antimicrob. Agents Chemother. 2020, 64.
  91. Zhu, Y.C.; Barat, S.A.; Borroto-Esoda, K.; Angulo, D.; Chaturvedi, S.; Chaturvedi, V. In vitro Efficacy of Novel Glucan Synthase Inhibitor, Ibrexafungerp (SCY-078), Against Multidrug- and Pan-resistant Candida auris Isolates from the Outbreak in New York. BioRxiv 2020.
  92. Chandra, J.; Mukherjee, P.K.; Leidich, S.D.; Faddoul, F.F.; Hoyer, L.L.; Douglas, L.J.; Ghannoum, M.A. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J. Dent. Res. 2001, 80, 903–908.
  93. Cowen, L.E.; Sanglard, D.; Howard, S.J.; Rogers, P.D.; Perlin, D.S. Mechanisms of Antifungal Drug Resistance. Cold Spring Harb. Perspect Med. 2014, 5, a019752.
  94. Ghannoum, M.; Long, L.; Sherif, R.; Abidi, F.Z.; Borroto-Esoda, K.; Barat, S.; Angulo, D.; Wiederhold, N. Determination of Antifungal Activity of SCY-078, a Novel Glucan Synthase Inhibitor, Against a broad panel of Rare Pathogenic Fungi. ASM Microbe Online 2020.
  95. Larkin, E.L.; Long, L.; Isham, N.; Borroto-Esoda, K.; Barat, S.; Angulo, D.; Wring, S.; Ghannoum, M. A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. Antimicrob. Agents Chemother. 2019, 63.
  96. Odds, F.C.; Brown, A.J.; Gow, N.A. Antifungal agents: Mechanisms of action. Trends Microbiol. 2003, 11, 272–279.
  97. Rocha, E.M.; Garcia-Effron, G.; Park, S.; Perlin, D.S. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 2007, 51, 4174–4176.
  98. Lamoth, F.; Alexander, B.D. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob. Agents Chemother. 2015, 59, 4308–4311.
  99. Wiederhold, N.P.; Najvar, L.K.; Jaramillo, R.; Olivo, M.; Pizzini, J.; Catano, G.; Patterson, T.F. Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata. J. Antimicrob. Chemother. 2018, 73, 448–451.
  100. Lepak, A.J.; Marchillo, K.; Andes, D.R. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob. Agents Chemother. 2015, 59, 1265–1272.
  101. Wring, S.A.; Randolph, R.; Park, S.; Abruzzo, G.; Chen, Q.; Flattery, A.; Garrett, G.; Peel, M.; Outcalt, R.; Powell, K.; et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob. Agents Chemother. 2017, 61.
  102. Ghannoum, M.; Isham, N.; Angulo, D.; Borroto-Esoda, K.; Barat, S.; Long, L. Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model. Antimicrob. Agents Chemother. 2020, 64.
  103. Vergidis, P.; Clancy, C.J.; Shields, R.K.; Park, S.Y.; Wildfeuer, B.N.; Simmons, R.L.; Nguyen, M.H. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS ONE 2016, 11, e0153247.
  104. Lee, A.; Prideaux, B.; Zimmerman, M.; Carter, C.; Barat, S.; Angulo, D.; Dartois, V.; Perlin, D.S.; Zhao, Y. Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model. Antimicrob. Agents Chemother. 2020, 64.
  105. Borroto-Esoda, K.; Barat, S.; Angulo, D.; Holden, K.; Warn, P. SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis. Open Forum Infect. Dis. 2017, 4, S472.
  106. Petraitis, V.; Petraitiene, R.; Katragkou, A.; Maung, B.B.W.; Naing, E.; Kavaliauskas, P.; Barat, S.; Borroto-Esoda, K.; Azie, N.; Angulo, D.; et al. Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1-->3)-beta-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 2020, 64.
  107. Barat, S.A.; Borroto-Esoda, K.; Angulo, D.; Ashbaugh, A.; Cushion, M. Efficacy of Ibrexafungerp (formerly SCY-078) in a Murine Treatment Model of Pneumocystis Pneumonia. ASM Microbe Online. 2019. Available online: (accessed on 5 January 2021).
  108. Spec, A.; Pullman, J.; Thompson, G.R.; Powderly, W.G.; Tobin, E.H.; Vazquez, J.; Wring, S.A.; Angulo, D.; Helou, S.; Pappas, P.G.; et al. MSG-10: A Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J. Antimicrob. Chemother. 2019, 74, 3056–3062.
  109. Wring, S.; Murphy, G.; Atiee, G.; Corr, C.; Hyman, M.; Willett, M.; Angulo, D. Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions. J. Clin. Pharmacol. 2018, 58, 1305–1313.
  110. Wring, S.; Murphy, G.; Atiee, G.; Corr, C.; Hyman, M.; Willett, M.; Angulo, D. Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus. Clin. Pharmacol. Drug Dev. 2019, 8, 60–69.
  111. Azie, N.; Angulo, D.; Dehn, B.; Sobel, J.D. Oral Ibrexafungerp: An investigational agent for the treatment of vulvovaginal candidiasis. Expert Opin. Investig. Drugs 2020, 29, 893–900.
  112. Juneja, D.; Singh, O.; Tarai, B.; Angulo, D. Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078) from the CARES Study. In Proceedings of the 29th ECCMID Congress, Amsterdam, The Netherlands, 13–16 April 2019.
  113. Cadet, R.; Tufa, M.; Angulo, D.; Nyirjesy, P. A Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp vs Fluconazole in Vulvovaginal Candidiasis (DOVE). Obstet. Gynecol. 2019, 133, 113S–114S.
  114. Schwebke, J.R.; Sorkin-Wells, V.; Azie, N.; Angulo, D.; Sobel, J. Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis: A phase 3, randomized, blinded, study vs. placebo (VANISH-303). IDSOG Oral Present. 2020, 223, 964–965.
  115. Scynexis. SCYNEXIS Announces Positive Top-Line Results from Its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection). SCYNEXIS, Inc. Press Release Online. 2020. Available online: (accessed on 29 December 2020).
  116. Scynexis. SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection). SCYNEXIS, Inc. Press Release Online. 2020. Available online: (accessed on 29 December 2020).
  117. Alexander, B.D.; Cornely, O.A.; Pappas, P.G.; Miller, R.; Johnson, M.; Vazquez, J.; Ostrosky-Zeichner, L.; Spec, A.; Rautemaa-Richardson, R.; Krause, R.; et al. Efficacy and Safety of Oral Ibrexafungerpin 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI). Poster Presented at ID Week 2020 Online. 2019. Available online: (accessed on 29 December 2020).
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback